U.S. market Closed. Opens in 2 hours 28 minutes

NAMS | NewAmsterdam Pharma Company N.V. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
Revenue12.76M95.91MN/AN/A
Cost of Revenue44.39KN/AN/AN/A
Gross Profit12.72M95.91MN/AN/A
Operating Expenses183.23M116.78M36.35M5.40M
Selling, General & Admin34.09M18.22M5.27M1.38M
Research & Development144.41M81.01M25.46M4.04M
Other Operating ExpensesN/AN/AN/AN/A
Operating Income-165.73M-3.32M-30.73M-5.43M
Other Expenses / Income5.49M-17.82M-5.98M-320.00K
Before Tax Income-160.25M-21.14M-36.71M-5.75M
Income Tax Expenses24.46KN/AN/AN/A
Net Income-160.27M-21.14M-36.71M-5.75M
Interest ExpensesN/AN/AN/AN/A
Basic Shares Outstanding82.16M18.97M17.75M17.75M
Diluted Shares Outstanding82.16M18.97M17.75M17.75M
EBITDA-165.69M-3.31M-30.73M-5.43M
EBITDA Margin-1,298.21%-3.45%0.00%0.00%
EBIT-160.25M-21.14M-36.71M-5.75M
EBIT Margin-1,255.57%-22.04%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙